Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)

Conditions: Colorectal Cancer; Minimal Residual Disease Interventions: Drug: Fludarabine Phosphate; Drug: Cyclophosphamide; Drug: Cetuximab; Drug: TROP2-CAR-NK Cells; Drug: Rimiducid (AP1903); Procedure: Lymphodepleting Chemotherapy Sponsors: M.D. Anderson Cancer Center; Bellicum Pharmaceuticals, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials